Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGSWW) Free Cash Flow (2020 - 2025)

GeneDx Holdings has reported Free Cash Flow over the past 6 years, most recently at -$7.4 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$7.4 million for Q4 2025, down 1202.45% from a year ago — trailing twelve months through Dec 2025 was $14.3 million (up 150.05% YoY), and the annual figure for FY2025 was $14.3 million, up 150.05%.
  • Free Cash Flow for Q4 2025 was -$7.4 million at GeneDx Holdings, down from $9.6 million in the prior quarter.
  • Over the last five years, Free Cash Flow for WGSWW hit a ceiling of $9.6 million in Q3 2025 and a floor of -$88.9 million in Q3 2022.
  • Median Free Cash Flow over the past 5 years was -$34.2 million (2023), compared with a mean of -$35.7 million.
  • Biggest five-year swings in Free Cash Flow: crashed 18437.87% in 2021 and later surged 284.09% in 2025.
  • GeneDx Holdings' Free Cash Flow stood at -$61.2 million in 2021, then rose by 2.5% to -$59.7 million in 2022, then skyrocketed by 51.78% to -$28.8 million in 2023, then surged by 98.02% to -$571000.0 in 2024, then tumbled by 1202.45% to -$7.4 million in 2025.
  • The last three reported values for Free Cash Flow were -$7.4 million (Q4 2025), $9.6 million (Q3 2025), and $8.1 million (Q2 2025) per Business Quant data.